Drug Development
The development of nicotinic acetylcholine receptor agonists began in the early 1990s after the discovery of nicotine’s positive effects on animal memory. The development of nicotinic acetylcholine receptor agonists has come a long way since then. The nicotinic acetylcholine receptor agonist are gaining increasing attention as drug candidates for multiple central nervous system disorders such as Alzheimer's disease, schizophrenia, attention-deficit hyperactivity disorder (ADHD) and nicotine addiction. Nicotinic acetylcholine receptors are receptors found in the central nervous system, the peripheral nervous systems and skeletal muscles. They are ligand-gated ion channels with binding sites for acetylcholine as well as other agonists. When agonists bind to a receptor it stabilizes the open state of the ion channel allowing influx of cations.
In 2009 there were at least five drugs on the market that affect the nicotinic acetylcholine receptors.
| Quinuclidine Carbamates | Quinuclidine Amides | Quinuclidine Ethers |
Read more about this topic: Nicotinic Agonist
Famous quotes containing the words drug and/or development:
“Whoever grows angry amid troubles applies a drug worse than the disease and is a physician unskilled about misfortunes.”
—Sophocles (497–406/5 B.C.)
“The work of adult life is not easy. As in childhood, each step presents not only new tasks of development but requires a letting go of the techniques that worked before. With each passage some magic must be given up, some cherished illusion of safety and comfortably familiar sense of self must be cast off, to allow for the greater expansion of our distinctiveness.”
—Gail Sheehy (20th century)